Physician profile
Paul Daniel Boerema
NPI 1396979233
$11,054.84
in general payments reported to CMS, 2019-2025
51 companies · $2,119 in 2025
The $2,119 reported for 2025 was more than what 94% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2020: $1,244 · 2021: $1,661 · 2022: $1,471 · 2023: $1,734 · 2024: $1,688 · 2025: $2,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,341 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,341.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,093.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,154.88 | 2020-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $1,124.75 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,007.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $672.97 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $437.61 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $384.40 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.31 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $329.65 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $313.67 | 2019-2025 | Trintellix |
| Amgen INC. | $293.80 | 2019-2025 | Repatha, Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $252.00 | 2021 | |
| Abbott Laboratories | $249.35 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $246.12 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $199.22 | 2019-2022 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $174.55 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $128.07 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $122.21 | 2023-2025 | Rexulti |
| Corcept Therapeutics | $115.40 | 2025 | Korlym |
| Astellas Pharma US INC | $109.24 | 2021-2024 | Veozah |
| Glaxosmithkline, LLC. | $101.34 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $83.29 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $81.32 | 2019-2022 | |
| Axsome Therapeutics, INC. | $81.07 | 2025 | Auvelity, Symbravo, Sunosi |
| Biohaven Pharmaceutical Holding Company Ltd. | $80.35 | 2022 | |
| Eisai INC. | $71.57 | 2020-2021 | |
| Allergan, INC. | $68.81 | 2019-2020 | |
| Inspire Medical Systems, INC. | $68.29 | 2024 | Inspire |
| Novartis Pharmaceuticals Corporation | $66.58 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $65.16 | 2023-2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $60.62 | 2022-2023 | Camzyos |
| Xeris Pharmaceuticals, INC. | $56.09 | 2023-2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.77 | 2024-2025 | Caplyta |
| Seqirus USA INC | $34.08 | 2024-2025 | Flucelvax, Fluad |
| Idorsia Pharmaceuticals US INC | $30.36 | 2022-2023 | Quviviq |
| Medtronic, INC. | $27.64 | 2024 | Intellis Adaptivestim |
| Halozyme INC | $26.61 | 2023 | |
| Jazz Pharmaceuticals INC. | $23.39 | 2022 | |
| Insulet Corporation | $21.79 | 2025 | Omnipod |
| Otsuka America Pharmaceutical, INC. | $19.57 | 2025 | Rexulti |
| Scilex Pharmaceuticals INC. | $17.20 | 2024 | |
| Paratek Pharmaceuticals, INC. | $16.72 | 2022 | |
| Upsher-Smith Laboratories LLC | $16.35 | 2021 | |
| Genentech USA, INC. | $15.93 | 2019 | |
| Smith+Nephew, INC. | $15.58 | 2024 | Collagenase Santyl |
| Acella Pharmaceuticals, LLC | $15.31 | 2024 | NP Thyroid 60 |
| Supernus Pharmaceuticals, INC. | $14.84 | 2021 | Tlando, Xyosted |
| Sanofi Pasteur INC. | $14.75 | 2023 | |
| Dexcom, INC. | $13.79 | 2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $13.03 | 2023 | Xyosted, Tlando, Nocdurna |
| Aytu Biopharma, INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Boerema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.